摘要
目的了解我国医药产业创新投资的现状,为优化其创新投资提供参考。方法从创新投资的规模、主体、来源、方式、成果等方面分析当前监管政策调整新形势下我国医药产业创新投资的现状及存在的主要问题,并有针对性地提出优化建议。结果我国医药企业普遍规模小、产值低、集中度低,创新投资金额整体偏低;化学药品制造企业创新投资的积极性相对较高,但创新投资资金来源有限,创新投资方式以技术改造为主,创新药品以仿制药为主。结论建议加速推进医药企业整合,提升企业创新投资水平;加大政府扶持力度,优化创新投资环境;拓宽融资渠道,扩大创新投资规模;制订完善的产业规划,发挥子行业创新优势。
Objective To understand the current situation of innovation investment in China's pharmaceutical industry,and to provide a reference for optimizing innovation investment in the pharmaceutical industry.Methods The current situation and main problems of innovative investment in China's pharmaceutical industry under the adjustment of new regulatory policies were analyzed from the scale,subject,source,mode and achievement of innovative investment,and targeted optimization suggestions were put forward.Results China's pharmaceutical enterprises generally have a small scale,low output value and low concentration,and the overall investment amount of innovation is low.Chemical manufacturing enterprises have relatively high enthusiasm for innovation investment,but the sources of innovation investment funds are limited.The investment mode of innovation is mainly technological transformation,and innovation is mainly generic drugs.Conclusion It is suggested to accelerate the integration of pharmaceutical enterprises,improve the level of enterprise innovation investment,increase government support,optimize the innovation investment environment,broaden financing channels,expand the scale of innovation investment,formulate sound industrial planning,and give full play to the innovation advantages of sub-industries.
作者
雒敏
黄亚新
LUO Min;HUANG Yaxin(School of Public Health Policy and Management,Nanjing Medical University,Nanjing,Jiangsu,China 211166;The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,China 210029)
出处
《中国药业》
CAS
2022年第5期13-16,共4页
China Pharmaceuticals
基金
江苏省高校哲学社会科学研究项目[2020SJA0308]
江苏省研究生科研与实践创新计划项目[SJCX20_0473]。
关键词
国家组织药品集中带量采购
药物一致性评价
药品审评审批
医药产业
创新投资
仿制药
national centralized drug-procurement
drug consistency evaluation
drug review and approval
pharmaceutical industry
innovation investment
generic drugs
